Pharma Tech

Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development

Jul 28, 2026, 10:26 AM

Read Full Article → Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development

Translate article text

Choose a language and wait for the translated text.

Apnimed will use the IPO funds to progress lead candidate oxnimbi, which could become the first pill to break onto the OSA market.